Adjuvant treatment for patients with renal cell carcinoma approved by FDA

The US Food and Drug Administration (FDA) has approved Sutent (sunitinib malate) for the adjuvant treatment for adult patients at a high risk of kidney cancer returning after nephrectomy. Read more

20 Nov 2017 14:45 News